Replies to post #543427 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

I agree. Another important point to keep in mind is that Liau has specifically stated that FDA mandated crossover for trial participants suffering from GBM. Most recently, she confirmed it during the JAMA interview that Dr. Low published here on iHub—I was so happy to hear her confirm this fact again … brain surgeons are always so precise and accurate it seems, and we need that kind of clarity amid all the noise.

Skip to timestamp 8:01. Dr. Liau again confirms that the crossover was mandated by the FDA.
https://edhub.ama-assn.org/jn-learning/audio-player/18738384

As NWBO moves toward the next step involving regulatory advisory, it is a good idea to review and fact check this important point once again.

We can hear more clear and precise commentary tomorrow:

Webinar with Dr. Linda Liau
December 5, 2022
8:30 PM Eastern Time
Topic: DCVax-L (murcidencel)

https://virtualtrials.org/webinar/

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/